

**NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE**

**Review Proposal Projects**

**NICE Technology Appraisal no. 197; Dronedarone for the treatment of nonpermanent atrial fibrillation**

**Provisional matrix of consultees and commentators**

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• Sanofi (dronedarone)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Action Heart</li> <li>• Afiya Trust</li> <li>• Anti Coagulation Europe (ACE)</li> <li>• Arrhythmia Alliance (AFA Affiliated)</li> <li>• Atrial Fibrillation Association (AFA)</li> <li>• Black Health Agency</li> <li>• British Cardiac Patients Association</li> <li>• Counsel and Care</li> <li>• Different Strokes</li> <li>• Equalities National Council</li> <li>• Grown Up Congenital Heart Patients Association</li> <li>• Heart Care Partnership (UK)</li> <li>• HEART UK</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Network of Sikh Organisations</li> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Stroke Association</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Anticoagulation Specialist Association (ASA)</li> <li>• British Association for Nursing in Cardiovascular Care</li> <li>• British Association for Service to the Elderly</li> <li>• British Association of Emergency Medicine</li> <li>• British Association of Stroke Physicians</li> <li>• British Atherosclerosis Society</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British Cardiovascular Industry Association</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• Healthcare Improvement Scotland</li> <li>• Medicines and Healthcare Products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Pharmacy Association</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• Abbott Healthcare Products (Propafenone)</li> <li>• Accord Healthcare (amiodarone, sotalol)</li> <li>• Actavis UK (amiodarone, flecainide)</li> <li>• Aurobindo Pharma (amiodarone, sotalol)</li> <li>• Bristol Laboratories (sotalol)</li> <li>• Bristol-Myers Squibb (sotalol)</li> <li>• Hameln Pharmaceuticals (amiodarone)</li> <li>• International Medication Systems (amiodarone)</li> <li>• Meda Pharmaceuticals (flecainide)</li> <li>• Mylan UK(sotalol)</li> </ul>

## Appendix A

Consultees	Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> <li>• British Cardiovascular Intervention Society (BCIS)</li> <li>• British Cardiovascular Society</li> <li>• British Geriatrics Society</li> <li>• British Heart Foundation</li> <li>• British Nuclear Cardiology Society</li> <li>• British Society for Haematology</li> <li>• British Society for Haemostasis and Thrombosis (BSHT)</li> <li>• British Society for Heart Failure</li> <li>• British Society of Cardiac Radiology</li> <li>• Clinical Leaders of Thrombosis (CLOT)</li> <li>• Heart Rhythm UK</li> <li>• National Heart Forum (UK)</li> <li>• Primary Care Cardiovascular Society</li> <li>• Royal College of Anaesthetists</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Pathologists</li> <li>• Royal College of Physicians</li> <li>• Royal College of Surgeons</li> <li>• Royal Society of Medicine</li> <li>• Society for Cardiological Science and Technology</li> <li>• Society of Cardiothoracic Surgeons of Great Britain and Ireland</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• Vascular Society</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• Somerset PCT Cluster</li> <li>• Swindon and Gloucestershire PCT Cluster</li> <li>• Welsh Government</li> </ul>	<ul style="list-style-type: none"> <li>• Sandoz (amiodarone)</li> <li>• Sanofi (amiodarone)</li> <li>• Teva UK(sotalol)</li> <li>• Zentiva UK(amiodarone, flecainide)</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Antithrombotic Trialists Collaboration (ATT)</li> <li>• British Society for Cardiovascular Research [BCS affiliated]</li> <li>• Cardiovascular Diseases Specialist Library (CVDSL)</li> <li>• Central Cardiac Audit Database</li> <li>• Cochrane Heart Group</li> <li>• Cochrane Peripheral Vascular Diseases Group</li> <li>• Cochrane Stroke Group</li> <li>• CODA</li> <li>• European Council for Cardiovascular Research</li> <li>• Heart Failure Research Group, University of Glasgow</li> <li>• MRC Clinical Trials Unit</li> <li>• National Heart Research Fund</li> <li>• National Institute for Health Research</li> <li>• Research Institute for the Care of Older People</li> <li>• Wellcome Trust - Cardiovascular Research Initiative</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• Assessment Group tbc</li> <li>• National Institute for Health Research Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Clinical Guidelines Centre</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul>

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed

any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

***PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS***

### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology are invited to prepare a submission dossier, can respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to prepare a submission dossier respond to consultations on the draft scope, the Assessment Report and the Appraisal Consultation Document. They can nominate clinical specialists and/or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but are not asked to prepare a submission dossier. Commentators are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

#### Assessment group

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies)) based on a systematic review of the manufacturer/sponsor and non-manufacturer/sponsor submission dossier to the Institute.